• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

European agents like IOP-lowering drug

Article

Fort Worth, TX?The European Medicines Agency's Committee for Medicinal Products for Human Use has reacted positively to the initial marketing authorization for Alcon Laboratories' travoprost 0.004%/ timolol 0.5% solution (DuoTrav) for lowering IOP.

Fort Worth, TX-The European Medicines Agency's Committee for Medicinal Products for Human Use has reacted positively to the initial marketing authorization for Alcon Laboratories' travoprost 0.004%/ timolol 0.5% solution (DuoTrav) for lowering IOP.

In a statement, Alcon said the approval sets the stage for marketing authorization of the solution within Europe. The authorization could be finalized during the second quarter of 2006, the company said.

The solution, administered as one drop daily, combines a beta blocker to decrease the production of aqueous humor with a prostaglandin analogue (travoprost) to increase the outflow of aqueous humor. It is approved in Australia and is under review in other countries.

Related Videos
John Saharek, president of ImprimisRX, speaks with Ophthalmology Times' David Hutton on three new products the company will be featuring during the American Academy of Ophthalmology's 2021 annual meeting
What keeps you up at night in ophthalmology: Part II
Chris Adams, Diopter Corp CEO
Ramin Valian, of Allergan, discusses pharmaceuticals in the glaucoma industry at Glaucoma 360
© 2024 MJH Life Sciences

All rights reserved.